QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
QQQ   317.08 (-1.13%)
AAPL   164.92 (+0.03%)
MSFT   282.30 (+0.71%)
META   168.53 (-1.01%)
GOOGL   116.63 (-0.57%)
AMZN   137.83 (-1.13%)
TSLA   850.00 (-2.44%)
NVDA   170.86 (-3.97%)
NIO   19.17 (-4.96%)
BABA   91.19 (+0.39%)
AMD   95.54 (-4.53%)
MU   59.15 (-3.74%)
T   18.10 (+0.56%)
CGC   2.87 (-12.50%)
GE   74.93 (-0.33%)
F   15.19 (-3.74%)
DIS   108.13 (-0.90%)
AMC   22.45 (-6.30%)
PYPL   94.48 (-1.85%)
PFE   49.78 (+0.42%)
NFLX   229.94 (-1.52%)
NASDAQ:CNTA

Centessa Pharmaceuticals - CNTA Stock Forecast, Price & News

$5.01
-0.17 (-3.28%)
(As of 08/9/2022 12:00 AM ET)
Add
Compare
Today's Range
$5.01
$5.69
50-Day Range
$3.18
$5.91
52-Week Range
$2.88
$25.98
Volume
48,745 shs
Average Volume
217,432 shs
Market Capitalization
$471.15 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.25

Centessa Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
104.6% Upside
$10.25 Price Target
Short Interest
Bearish
6.36% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-1.00mentions of Centessa Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Selling Shares
$342,215 Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.18) to ($1.73) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

656th out of 1,098 stocks

Pharmaceutical Preparations Industry

323rd out of 536 stocks

CNTA stock logo

About Centessa Pharmaceuticals (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.

Analysts Set New Price Targets

A number of research analysts have recently issued reports on the stock. Morgan Stanley cut their target price on shares of Centessa Pharmaceuticals from $15.00 to $10.00 and set an "overweight" rating for the company in a research note on Friday, July 15th. The Goldman Sachs Group dropped their price objective on shares of Centessa Pharmaceuticals from $12.00 to $8.00 and set a "neutral" rating for the company in a research report on Tuesday, May 24th. Jefferies Financial Group cut shares of Centessa Pharmaceuticals from a "buy" rating to a "hold" rating and set a $4.00 price objective for the company. in a research report on Friday, June 3rd. Finally, BMO Capital Markets assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, June 16th. They set an "outperform" rating and a $19.00 target price for the company.

Centessa Pharmaceuticals Trading Up 0.6 %

Shares of CNTA Stock traded up $0.03 on Tuesday, hitting $5.21. The stock had a trading volume of 880 shares, compared to its average volume of 139,619. Centessa Pharmaceuticals has a twelve month low of $2.88 and a twelve month high of $25.98. The firm has a market cap of $489.95 million, a P/E ratio of -2.19 and a beta of 0.27. The company has a current ratio of 21.37, a quick ratio of 21.37 and a debt-to-equity ratio of 0.16. The company has a fifty day moving average price of $4.64 and a two-hundred day moving average price of $7.05.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Rating) last posted its quarterly earnings data on Monday, May 16th. The company reported ($0.60) EPS for the quarter, beating the consensus estimate of ($0.69) by $0.09. As a group, analysts forecast that Centessa Pharmaceuticals will post -2.18 earnings per share for the current fiscal year.

Insider Activity at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, EVP Antoine Yver sold 20,222 shares of the business's stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $5.42, for a total transaction of $109,603.24. Following the sale, the executive vice president now directly owns 813,675 shares of the company's stock, valued at approximately $4,410,118.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. In related news, CEO Saurabh Saha acquired 10,000 shares of the company's stock in a transaction that occurred on Friday, June 24th. The stock was acquired at an average price of $4.63 per share, with a total value of $46,300.00. Following the purchase, the chief executive officer now directly owns 38,000 shares in the company, valued at $175,940. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Antoine Yver sold 20,222 shares of the firm's stock in a transaction on Tuesday, May 17th. The shares were sold at an average price of $5.42, for a total transaction of $109,603.24. Following the transaction, the executive vice president now directly owns 813,675 shares of the company's stock, valued at approximately $4,410,118.50. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 68,945 shares of company stock valued at $342,215. 9.09% of the stock is owned by corporate insiders.

Receive CNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNTA Stock News Headlines

4 Analysts Have This to Say About Centessa Pharmaceuticals
Centessa Pharmaceuticals GAAP EPS of -$0.60
See More Headlines
Receive CNTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Centessa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

CNTA Company Calendar

Last Earnings
5/16/2022
Today
8/09/2022
Next Earnings (Estimated)
8/15/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CNTA
Fax
N/A
Employees
70
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.25
High Stock Price Forecast
$19.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+104.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
4 Analysts

Profitability

Net Income
$-381,900,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$5.47 per share

Miscellaneous

Free Float
85,493,000
Market Cap
$471.15 million
Optionable
Not Optionable
Beta
0.27

Key Executives

  • Dr. Saurabh Saha M.D. (Age 45)
    Ph.D., CEO & Director
    Comp: $987.21k
  • Dr. Gregory M. Weinhoff M.B.A. (Age 51)
    M.D., MBA, Chief Financial Officer
    Comp: $537.5k
  • Dr. Antoine Yver M.D. (Age 64)
    M.Sc., MSc, Exec. VP & Chairman of Devel.
    Comp: $449.58k
  • Ms. Marella Thorell (Age 55)
    Chief Accounting Officer
  • Dr. Thomas S. Templeman Ph.D. (Age 62)
    Chief Technology Officer
  • Dr. David M. Chao Ph.D. (Age 54)
    Chief Admin. Officer
  • Ms. Jennifer Porcelli
    Head of Investor Relations
  • Mr. Iqbal J. Hussain L.L.B. (Age 41)
    Gen. Counsel, Chief Compliance Officer & Corp. Sec.
  • Ms. Kristen K. Sheppard Esq.
    J.D., Sr. VP of Investor Relations & Corp. Communications
  • Ms. Tia L. Bush (Age 51)
    Chief Quality Officer













CNTA Stock - Frequently Asked Questions

Should I buy or sell Centessa Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Centessa Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CNTA shares.
View CNTA analyst ratings
or view top-rated stocks.

What is Centessa Pharmaceuticals' stock price forecast for 2022?

4 analysts have issued 1-year target prices for Centessa Pharmaceuticals' shares. Their CNTA share price forecasts range from $4.00 to $19.00. On average, they anticipate the company's share price to reach $10.25 in the next year. This suggests a possible upside of 104.6% from the stock's current price.
View analysts price targets for CNTA
or view top-rated stocks among Wall Street analysts.

How has Centessa Pharmaceuticals' stock performed in 2022?

Centessa Pharmaceuticals' stock was trading at $11.26 at the start of the year. Since then, CNTA shares have decreased by 55.5% and is now trading at $5.01.
View the best growth stocks for 2022 here
.

When is Centessa Pharmaceuticals' next earnings date?

Centessa Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, August 15th 2022.
View our CNTA earnings forecast
.

How were Centessa Pharmaceuticals' earnings last quarter?

Centessa Pharmaceuticals plc (NASDAQ:CNTA) issued its quarterly earnings data on Monday, May, 16th. The company reported ($0.60) earnings per share for the quarter, topping analysts' consensus estimates of ($0.69) by $0.09.

When did Centessa Pharmaceuticals IPO?

(CNTA) raised $285 million in an initial public offering (IPO) on Friday, May 28th 2021. The company issued 15,000,000 shares at a price of $18.00-$20.00 per share. Morgan Stanley and Goldman Sachs acted as the underwriters for the IPO and Jefferies and Evercore ISI were co-managers.

What is Centessa Pharmaceuticals' stock symbol?

Centessa Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNTA."

Who are Centessa Pharmaceuticals' major shareholders?

Centessa Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include TD Asset Management Inc. (0.09%) and Mirae Asset Global Investments Co. Ltd. (0.06%). Insiders that own company stock include (Bermuda) Ltd Gap, Aaron Kantoff, Antoine Yver, David J Grainger, Medicxi Ventures Management (J, Rubertis Francesco De, Saurabh Saha and Tia L Bush.
View institutional ownership trends
.

How do I buy shares of Centessa Pharmaceuticals?

Shares of CNTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Centessa Pharmaceuticals' stock price today?

One share of CNTA stock can currently be purchased for approximately $5.01.

How much money does Centessa Pharmaceuticals make?

Centessa Pharmaceuticals (NASDAQ:CNTA) has a market capitalization of $471.14 million. The company earns $-381,900,000.00 in net income (profit) each year or ($2.38) on an earnings per share basis.

How many employees does Centessa Pharmaceuticals have?

Centessa Pharmaceuticals employs 70 workers across the globe.

How can I contact Centessa Pharmaceuticals?

Centessa Pharmaceuticals' mailing address is THE DOROTHY HODGKIN BUILDING BABRAHAM RESEARCH CAMPUS, BABRAHAM CAMBRIDGE X0, CB22 3FH. The official website for the company is www.centessa.com. The company can be reached via phone at 44-73-9178-9784 or via email at investorrelations@centessa.com.

This page (NASDAQ:CNTA) was last updated on 8/9/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.